Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program

References

• Naghavi M , AbajobirAA, AbbafatiCet al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980- 2013;2016: a systematic analysis for the Global Burden of Disease Study 2016 . Lancet390 ( 10100 ), 1151 – 1210 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Ference BA , GinsbergHN, GrahamIet al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel . Eur. Heart J.38 ( 32 ), 2459 – 2472 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Ference BA , YooW, AleshIet al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis . J. Am. Coll. Cardiol.60 ( 25 ), 2631 – 2639 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sabatine MS , GiuglianoRP, KeechACet al. Evolocumab and clinical outcomes in patients with cardiovascular disease . N. Engl. J. Med.376 ( 18 ), 1713 – 1722 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Steg PG . Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab – ODYSSEY OUTCOMES . Presented at : American College of Cardiology Annual Meeting . Orlando, FL, USA, 10 March 2018 . www.acc.org/latest-in-cardiology/clinical-trials/2018/03/09/08/02/odyssey-outcomes .
   Google Scholar
• Boekholdt SM , HovinghGK, MoraSet al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events . J. Am. Coll. Cardiol.64 ( 5 ), 485 – 494 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators . The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials . Lancet380 ( 9841 ), 581 – 590 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cannon CP , KhanI, KlimchakAC, ReynoldsMR, SanchezRJ, SasielaWJ . Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease . JAMA Cardiol.2 ( 9 ), 959 – 966 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Stroes ES , ThompsonPD, CorsiniAet al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management . Eur. Heart J.36 ( 17 ), 1012 – 1022 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zhang H , PlutzkyJ, SkentzosSet al. Discontinuation of statins in routine care settings, a cohort study . Ann. Intern. Med.158 ( 7 ), 526 – 534 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cohen JD , BrintonEA, ItoMK, JacobsonTA . Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users . J. Clin. Lipidol.6 ( 3 ), 208 – 215 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Krempf M , SimpsonRJJ, RameyDRet al. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey . Lipids Health Dis.14, 45 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Steen DL , KhanI, AnsellD, SanchezRJ, RayKK . Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines . BMJ Open7 ( 2 ), e013255 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Source: US FDA . FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease ( 2018 ). Press release : www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616518.htm .
   Google Scholar
• Abifadel M , VarretM, RabèsJ-Pet al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia . Nat. Genet.34, 154 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Cohen JC , BoerwinkleE, MosleyTHJr, HobbsHH . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease . N. Engl. J. Med.354 ( 12 ), 1264 – 1272 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Stein EA , MellisS, YancopoulosGDet al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol . N. Engl. J. Med.366 ( 12 ), 1108 – 1118 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhang X-L , ZhuQ-Q, ZhuLet al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials . BMC Med.13 ( 1 ), 123 ( 2015 ).
   PubMedGoogle Scholar
• Raal F , ScottR, SomaratneRet al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition . Circulation126 ( 20 ), 2408 – 2417 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hines D , RaneP, PatelJ, HarrisonD, WadeR . Persistance and adherence with proprotein convertase subtilisin/kexin type 9 inhibitors in clinical practice . J. Am. Coll. Cardiol.69 ( 11 Suppl. ), 159 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Ray KK , LandmesserU, LeiterLAet al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol . N. Engl. J. Med.376 ( 15 ), 1430 – 1440 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Ray KK , StoekenbroekRM, KallendDet al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: pre-specified secondary end points in ORION 1 . Circulation138 ( 13 ), 1304 – 1316 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Fitzgerald K , WhiteS, BorodovskyAet al. A highly durable RNAi therapeutic inhibitor of PCSK9 . N. Engl. J. Med.376 ( 1 ), 41 – 51 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Fitzgerald K , Frank-KamenetskyM, Shulga-MorskayaSet al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase 1 trial . Lancet383 ( 9911 ), 60 – 68 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ray KK , LandmesserU, LeiterLAet al. Impact of a 1- or 2-dose starting regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year . Presented at : ESC Congress . Barcelona, Spain ( 2017 ).
   Google Scholar
• Bangalore S , FayyadR, MesserliFHet al. Relation of variability of low-density lipoprotein cholesterol and blood pressure to events in patients with previous myocardial infarction from the IDEAL trial . Am. J. Cardiol.119 ( 3 ), 379 – 387 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Bangalore S , BreaznaA, DeMiccoDA, WunC-C, MesserliFH . Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes . J. Am. Coll. Cardiol.65 ( 15 ), 1539 – 1548 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Atkinson MJ , KumarR, CappelleriJC, HassSL . Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers . Value Health8 ( Suppl. 1 ), S9 – S24 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Atkinson MJ , SinhaA, HassSLet al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease . Health Qual. Life Outcomes2, 12 ( 2004 ).
   PubMedGoogle Scholar
• Catapano AL , GrahamI, De BackerGet al. 2016 ESC/EAS guidelines for the management of dyslipidaemias . Eur. Heart J.37 ( 39 ), 2999 – 3058 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Robinson JG , HuijgenR, RayK, PersonsJ, KasteleinJJP, PencinaMJ . Determining when to add nonstatin therapy: a quantitative approach . J. Am. Coll. Cardiol.68 ( 22 ), 2412 – 2421 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Wiegman A , GiddingSS, WattsGFet al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment . Eur. Heart J.36 ( 36 ), 2425 – 2437 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Huijgen R , KindtI, DefescheJC, KasteleinJJP . Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants . Eur. Heart J.33 ( 18 ), 2325 – 2330 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Huijgen R , HuttenBA, KindtI, VissersMN, KasteleinJJP . Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH . Circ. Cardiovasc. Genet.5 ( 3 ), 354 – 359 ( 2012 ).
   PubMedGoogle Scholar
• Kusters DM , WiegmanA, KasteleinJJP, HuttenBA . Carotid intima-media thickness in children with familial hypercholesterolemia . Circ. Res.114 ( 2 ), 307 – 310 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Besseling J , HovinghGK, HuijgenR, KasteleinJJP, HuttenBA . Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality . J. Am. Coll. Cardiol.68 ( 3 ), 252 – 260 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hartgers ML , BesselingJ, StroesESet al. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: a model that explores the efficacy of conventional and novel lipid-lowering therapy . J. Clin. Lipidol.12 ( 4 ), 972 – 980.e1 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Kastelein JJP , HovinghGK, LangsletGet al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia . J. Clin. Lipidol.11 ( 1 ), 195.e4 – 203.e4 ( 2017 ).
   Web of Science ®Google Scholar
• Khera AV , ChaffinM, AragamKGet al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations . Nat. Genet.50 ( 9 ), 1219 – 1224 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Cuchel M , BruckertE, GinsbergHNet al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society . Eur. Heart J.35 ( 32 ), 2146 – 2157 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Thompson GR , BlomDJ, MaraisAD, SeedM, PilcherGJ, RaalFJ . Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol . Eur. Heart J.39 ( 14 ), 1162 – 1168 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Raal FJ , HonarpourN, BlomDJet al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial . Lancet385 ( 9965 ), 341 – 350 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Raal FJ , HovinghGK, BlomDet al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study . Lancet Diabetes Endocrinol.5 ( 4 ), 280 – 290 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Stein EA , HonarpourN, WassermanSM, XuF, ScottR, RaalFJ . Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia . Circulation128 ( 19 ), 2113 – 2120 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kallend D . Efficacy and safety of inclisiran, an RNAi therapeutic targeting PCSK9: analysis of dosage in different Phase II subgroups and populations . Presented at : NLA Annual Meeting . Las Vegas, NV, USA, 30 April 2018 . www.businesswire.com/news/home/20180430005266/en/Medicines-Company-Presents-New-Data-National-Lipid .
   Google Scholar
• Sidney S , QuesenberryCPJr, JaffeMGet al. Recent trends in cardiovascular mortality in the United States and public health goals . JAMA Cardiol.1 ( 5 ), 594 – 599 ( 2016 ).
   PubMed Web of Science ®Google Scholar